Targeting HERI/EGFR: A molecular approach to cancer therapy

被引：197
作者：
Arteaga, C
机构：
[1] Vanderbilt Univ, Sch Med,Div Oncol, Dept Med,Breast Canc Res Program, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med,Div Oncol, Dept Canc Biol,Breast Canc Res Program, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA
来源：
SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 03期
关键词：
D O I：
10.1016/S0093-7754(03)00185-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 14
页数：12
相关论文
共 97 条
[1]   Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].
Agus, DB ;
Akita, RW ;
Fox, WD ;
Lewis, GD ;
Higgins, B ;
Pisacane, PI ;
Lofgren, JA ;
Tindell, C ;
Evans, DP ;
Maiese, K ;
Scher, HI ;
Sliwkowski, MX .
CANCER CELL, 2002, 2 (02) :127-137
[2]  
Akita Robert W., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1003
[3]   ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression [J].
Anderson, NG ;
Ahmad, T ;
Chan, K ;
Dobson, R ;
Bundred, NJ .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) :774-782
[4]  
[Anonymous], P AM SOC CLIN ONCOL
[5]  
Arteaga CL, 2002, ONCOLOGIST, V7, P31
[6]  
Arteaga CL, 2001, J CLIN ONCOL, V19, p32S
[7]   ZD1839 ('Iressa')1,2 as an anticancer agent [J].
Baselga, J ;
Averbuch, SD .
DRUGS, 2000, 60 (Suppl 1) :33-40
[8]   HER-targeted tyrosine-kinase inhibitors [J].
Baselga, J ;
Hammond, LA .
ONCOLOGY, 2002, 63 :6-16
[9]   Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer:: Pivotal trials [J].
Baselga, J .
ONCOLOGY, 2001, 61 :14-21
[10]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
12345678910